Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02487745
Other study ID # IRB00046990
Secondary ID R01DA037314-01A1
Status Completed
Phase N/A
First received
Last updated
Start date November 2015
Est. completion date September 2020

Study information

Verified date July 2022
Source Johns Hopkins University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this clinical trial is to evaluate the effectiveness and economic benefits of a Wage Supplement Model of arranging long-term exposure to employment-based abstinence reinforcement.


Description:

Read more »
Read more »

Study Design


Intervention

Behavioral:
Abstinence-contingent wage supplements
Before obtaining competitive employment, participants will be able to earn wage supplements for attending two individual placement and support (IPS) supported employment sessions per week, and for completing specific tasks prescribed by IPS including developing a worker profile, applying for appropriate jobs, and completing job interviews. Once a participant becomes employed, participants will be able to earn up to $5 per hour for every hour worked in a competitive job up to 40 hours per week verified by pay stubs. To maintain long-term drug abstinence, participants will be required to provide urine samples to earn the maximum in wage supplements.
Individual Placement and Support (IPS) supported employment
Individual Placement and Support (IPS) supported employment involves rapid job search, promotes competitive employment, considers the participant's preferences, and provides job supports and benefits counseling. An employment specialist will establish relationships will potential employers and work with participants to identify potential jobs, prepare applications, and to apply for positions.

Locations

Country Name City State
United States Center for Learning and Health Baltimore Maryland

Sponsors (2)

Lead Sponsor Collaborator
Johns Hopkins University National Institute on Drug Abuse (NIDA)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Cost-benefit of Treatment The Cost-Benefit Analysis (CBA) will compare the monetized benefits relative to costs 2 years
Primary The Percentage of Opiate- and Cocaine-negative Urine Samples (# opiate- and cocaine-negative urine samples/divided by possible #) x 100 1 year
Primary The Percentage of Participants Who Are Employed (# participants employed /divided by total # of participants) x 100 1 year
Secondary The Percentage of Participants Who Report Injecting Drugs (# participants reporting injecting drugs /divided by total # of participants) x 100 1 year
Secondary The Percentage of Participants Who Report Trading Unprotected Sex for Drugs or Money (# participants reporting trading unprotected sex for drugs or money/divided by total # of participants) x 100 1 year
Secondary The Percentage of Participants Who Report Sharing Injection Equipment (# participants reporting sharing injection equip/divided by total # of participants) x 100 1 year
Secondary The Percentage of Participants With Household Incomes Below the Federal Poverty Level (# participants with incomes below federal poverty level/divided by total # of participants) x 100 1 year
Secondary The Percentage of Opiate- and Cocaine-negative Urine Samples Post-intervention This will be measured after the intervention ends Year 2
Secondary The Percentage of Participants Who Are Employed Post-intervention This will be measured after the intervention ends Year 2
Secondary The Percentage of Participants Who Report Injecting Drugs Post-intervention This will be measured after the intervention ends Year 2
Secondary The Percentage of Participants Who Report Trading Unprotected Sex for Drugs or Money Post-intervention This will be measured after the intervention ends Year 2
Secondary The Percentage of Participants Who Report Sharing Injection Equipment Post-intervention This will be measured after the intervention ends Year 2
See also
  Status Clinical Trial Phase
Completed NCT00726557 - Post-marketing Surveillance Study of Ex-intravenous Drug Abusers With Chronic Hepatitis C Treated With PegIntron Plus Rebetol (P04408/MK-4031-261) N/A
Completed NCT04556552 - Non-Invasive Vagal Nerve Stimulation in Opioid Use Disorders Phase 3
Completed NCT03093415 - Hepatitis C Treatment in PWIDs: MAT or Syringe Exchange Assisted-therapy vs Standard of Care Phase 4
Completed NCT02797990 - Conflict Between Maternal Autonomy and Child Health in Substance-use N/A
Completed NCT01031745 - Contingency Management in the Delivery of HAART to Drug Users in Chennai, India Phase 2
Completed NCT02774954 - Change the Cycle: An RCT to Prevent Injection Initiation N/A
Completed NCT00471042 - Study of Buprenorphine Maintenance Treatment for Opioid Dependence in Primary Care
Completed NCT02796027 - BRIDGE: Improving HIV Service Delivery for People Who Inject Drugs N/A
Completed NCT00149669 - Employment-based Reinforcement of Naltrexone Ingestion and Abstinence N/A
Recruiting NCT03502525 - Break the Cycle: Prevention for Reducing Initiation Into Injection Drug Use N/A
Completed NCT00244374 - A Randomized Trial of Vaccine Adherence in Young Injection Drug Users N/A
Completed NCT00023283 - Counseling Conditions for Buprenorphine in a Primary Care Clinic - 1 Phase 2
Completed NCT00249470 - The Therapeutic Workplace Initiation Study N/A